Xilio Therapeutics, Inc. (XLO)

Market Cap	59.81M +37.2%
Revenue (ttm)	64.09M +327.3%
Net Income	-21.83M
EPS	-3.32
Shares Out	6.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,986
Open	9.11
Previous Close	9.05
Day's Range	9.05 - 9.26
52-Week Range	6.47 - 12.59
Beta	-0.12
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 22, 2021
• Employees: 76
• Stock Exchange: Nasdaq
• Ticker Symbol: XLO
• Website: https://xiliotx.com

Financial Performance

In 2025, Xilio Therapeutics's revenue was $43.77 million, an increase of 589.88% compared to the previous year's $6.34 million. Losses were -$35.04 million, -39.84% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 12, 2026

Data Sources Report a data error